| YEAR EVENTS
2000 - Wockhardt has launched cardiac drug enalapril maleate in the US through its marketing joint venture with Sidmak Laboratories.
- Pharmaceutical major Wockhardt Ltd has set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad.
2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of Wockhardt Ltd, will set up two cardiac hospitals in Mumbai and Bangalore.
- The Company has terminated its three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic pharma companies in the US.
- Pharma major Wockhardt Ltd. has entered into a strategic alliance with a Japanese firm Eisai Company Ltd. to manufacture and market a neurology drug -- Methycobal.
- Wockhardt Hospitals Ltd, the wholly owned subsidiary of pharmaceutical major Wockhardt Ltd, has tied up with four international health insurance companies to offer medical cover to non-resident Indians.
- AGM JUNE 8 2001 Wockhardt has launched an innovative and attractive employee stock option scheme, ESOP.
- Wockhardt Ltd has introduced an employee stock option (ESOP) scheme for over 175 employees in the senior and middle management levels with about 2,00,000 shares being allotted.
2002
-The Hari L Mundra has joined Wockhardt as vice-chairman. Mundra will spearhead the company's domestic operations which account for 70 per cent of its turnover.
- Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director on its Corporate Board. Mr. Kumar will spearhead Wockhardt's International Business covering bulk drug operations and formulations export, as well as ANDA research and Intellectual Property Rights.
2003
-Wockhardt restructured its field organization to upgrade its competitiveness and productivity.
-Mumbai based wockhardt will hit the domestic market with the first indigenously developed insulin soon, in a move to induce turmoil in the market.
-Wockhardt has launched new four speciality hospitals at its Mulund complex in Mumbai.
-Maharashtra Government decided to terminate its Joint Venture agreement with Wockhardt for setting up a super speciality hospital.
-Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd, along with its subsidiaries.
-Wockhardt is strengthening its marketing strategies and distribution system to unveil human insulin in Indian market.
-Wockhardt Launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product.
-Wockhardt Ltd has received USFDA approval for marketing bethanecol Chloride tablets in the US.
-Wockhardt baged USFDA approval for Bethanechol
-Baged US approval to sell bethanechol chloride tablets
-Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on the board of the company as Executive Director, has resigned from the directorship with immediate effect.
2004
-Wockhardt Ltd has filed an Investigational New Drug (IND) application for its new drug for respiratory infections, WCK-1152
- Wockhardt Ltd has acquired German pharmaceutical company esparma GmbH for a consideration of $11 million (around Rs 49 crore).
-Centre for Drug Evaluation & Research, an arm of the US Food & Drug Administration (US FDA), has approved the sterile injectable facility as well as facilities for sterile bulk drugs (active pharmaceutical ingredient) and formulations spread over three locations in India
-Wockhardt gets USFDA nod for 6 manufacturing units
2005
-Launches of India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients on February 14, 2005
-Wockhardt forges alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad
-Wockhardt unveils father`s heart network
-Wockhardt receives US FDA approval for marketing cefuroxime axetil in the US market
-Wockhardt unveils new generation hepatitis A vaccine
-Wockhardt rolls out new Hepatitis A vaccine
2006
-Wockhardt's Waluj plant approved by US FDA
2007
-Wockhardt signs in-licensing pact with Crawford Healthcare of UK.
-Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance & Information for a period of five years effective from February 22, 2007, subject to the approval of shareholders.
-Wockhardt Ltd has announced US FDA approval for marketing Ketorolac anti-inflammatory injection in the US market, its third US FDA approval in the last ten days.
- Wockhardt Ltd on May 03, 2007 has announced the acquisition of Negma Laboratories, the fourth largest independent, integrated pharmaceutical group in France with sales of $ 150 million. The Company has acquired Negma Laboratories in an all-cash deal worth $ 265 million. The transaction is valued at 1.8 times the sales and 9.7 times the EBITDA.
2008
Wockhardt Ltd has unveiled Cetirizine tablets in the US, after having got the regulatory clearance to market different strengths of anti-allergy medicine Cetirizine Hydrochloride. Cetirizine is the generic version of Pfizer's Zyrtec brand and the total market for Cetirizine tablets in the US is $1.4 billion.
- Wockhardt Ltd has forayed into a 10- year in-licensing pact with the UK's Sinclair Pharma plc to market dermatology and dental products in India.
2009
-A biotechnology breakthrough in Diabetes Wockhardt launches new insulin (Glaritus) in India.
-Harvard Medical School Professor shows connection of Cancer and Heart diseases with Diabetes.
-Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala.
-Wockhardt launches anti-hypertensive drug Nicardipine injections in USA.
-Wockhardt wins Government of India Patent Award.
-Wockhardt appoints BDO Haribhakti as auditor.
-Wockhardt announces Entacapone patent settlement with Orion Corporation.
2010
-Wockhardt receives US FDA approval for antibacterial Levofloxacin
-Wockhardt launches Prostate drug Flomax in the United States on Day-1.
-Wockhardt receives US FDA approval for the generic version of Toprol XLr, a cardiac drug.
2011
-Wockhardt launches generic version of Protonixr tablets in the US.
-Wockhardt receives US FDA approval for generic version of Effexor XRr capsules.
-Wockhardt launches three new products in three weeks, in the United States.
-Wockhardt receives tentative US FDA approval for generic version of Patanolr ophthalmic solution.
2012
-Wockhardt launches generic version of anti--ulcer drug Prevacidr.
-Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XLr.
-Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodonr.
-Wockhardt receives US FDA approval for generic version of Parkinson's drug Comtanr.
2013
-Wockhardt receives the 'Best Enterprise' award from the Europe.
-Wockhardt launches generic version of anti-convulsant drug Lamictal XR.
2014
-Wockhardt's drug discovery gets a boost with fast track approval by USFDA.
2015
-Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid
-Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA
-US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt
2015
-Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA
-Wockhardt receives ANDA approval for pain medication Oxycodone liquid
-Wockhardt gains over 2% after MHRA completes plant inspection
-Wockhardt gets QIDP status for new antibiotic from US FDA.
2016
-Wockhardt Ltd has acquisition of 100% stake in Wockhardt France (Holdings) S.A.S
2017
-Wockhardt has received US FDA approval for Eye Drop for treating Ophthalmic Allergies
-Wockhardt Receives Acknowledgement Of Its Breakthrough Superdrug Antibiotic Wck 5222 For Phase III Clinical Trial From Us FDA
-Wockhardt Receives approval from IS FDA for an ANDA 1gm and 2gm injections of oxacillin
2018
-Wockhardt sets up its first manufacturing facility in Middle East for manufacture of new chemical entities
2019
-Wockhardt Receives US FDA for 100mg and 400mg tablets of Imatinib Mesylate, which is used to treat many kinds of cancers and tumors
-Wockhardt Receives US FDA Approval for Prostate cancer drug
2020
-Wockhardt entered into an agreement with the UK Government to fill finish COVID-19 vaccines.
-Wockhardt received Qualified Infectious Disease Product (QIDP) designation from the US health regulator for its combination antibiotic, WCK 6777.
-Wockhardt gets DCGI nod for 2 new antibiotics.
2021
-RDIF and Wockhardt partner to produce Sputnik V and Sputnik Light vaccines against COVID- 19
-Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
2022
-The company issued rights shares of Rs. 5 in the ratio of 3:10 at a premium of Rs. 220 per share.
-Wockhardt receives affirmation in credit ratings from CARE.
|